Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.2
3.0
Journals
Animals
Special Issues
Companion Animals’ Molecular Oncology
share announcement

Companion Animals’ Molecular Oncology

A special issue of Animals (ISSN 2076-2615). This special issue belongs to the section "Companion Animals".

Deadline for manuscript submissions: 20 October 2024 | Viewed by 3695

Special Issue Editors

Prof. Dr. María Dolores Llobat Bordes

E-Mail Website
Guest Editor
Department of Animal Production and Health, Veterinary Public Health and Food Science and Technology (PASAPTA), Facultad de Veterinaria, Universidad Cardenal Herrera-CEU, CEU Universities, 46113 Valencia, Spain
Interests: companion animals; molecular biology; molecular genetics; oncology
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Pablo Jesús Marín-García

E-Mail Website
Guest Editor
Department of Animal Production and Health, Veterinary Public Health and Food Science and Technology (PASAPTA), Facultad de Veterinaria, Universidad Cardenal Herrera-CEU, CEU Universities, 46113 Valencia, Spain
Interests: statistic analysis; OMICs; metabolomics; nutrition; animal; protein
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Veterinary medicine has advanced tremendously in recent years. Thanks to the application of molecular technologies and omics techniques, we can discover the mechanisms that underlie different diseases and pathological stages. Among these, oncology is a branch of veterinary medicine that can benefit from these advances. Pet owners are increasingly interested in improving the quality of life and pathologies of their pets. In addition, the use of companion animals as animal models for human pathologies is becoming more frequent. All these reasons make the study of the molecular mechanisms of oncological processes increasingly important for clinical research in veterinary medicine.

We invite original research papers that address the molecular mechanisms underlying the oncologic pathologies in companion animals, and new treatments with demonstrated results. Areas of interest include tumor development and progression, molecular mechanisms of pathology, genetics aspects, and treatments of solid or not solid tumors in companion animals, including mainly cats and dogs, although papers about other companion animals will be welcome.

Prof. Dr. María Dolores Llobat Bordes
Prof. Dr. Pablo Jesús Marín-García
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Animals is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • molecular mechanisms
  • veterinary oncology
  • treatments
  • genetics

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

17 pages, 3518 KiB  
Article
Diagnosis of Canine Tumours and the Value of Combined Detection of VEGF, P53, SF and NLRP3 for the Early Diagnosis of Canine Mammary Carcinoma
by Ning-Yu Yang, Hui-Hua Zheng, Chao Yu, Yan Ye and Guang-Hong Xie
Animals 2024, 14(9), 1272; https://doi.org/10.3390/ani14091272 - 24 Apr 2024
Viewed by 270
Abstract
The average life of a dog is generally maintained at ten to fifteen years, and tumours are the predominant reason that leads to the death of dogs, especially canine mammary carcinoma. Therefore, early diagnosis of tumours is very important. In this study, tumor [...] Read more.
The average life of a dog is generally maintained at ten to fifteen years, and tumours are the predominant reason that leads to the death of dogs, especially canine mammary carcinoma. Therefore, early diagnosis of tumours is very important. In this study, tumor size, morphology, and texture could be seen through general clinical examination, tumor metastasis could be seen through imaging examination, inflammatory reactions could be seen through hematological examination, and abnormal cell morphology could be seen through cytological and histopathological examination. In the 269 malignant cases and 179 benign cases, we randomly selected 30 cases each, and an additional 30 healthy dogs were selected for the experiment (healthy dogs: dogs in good physical condition without any tumor or other diseases). We used RT-qPCR and ELISA to determine the relative expression of vascular endothelial growth factor (VEGF), tumor protein P53 (P53), serum ferritin (SF), and NOD-like receptor protein 3 (NLRP3) in 30 healthy dogs, 30 dogs with benign mammary tumours, and 30 dogs with malignant mammary tumours. In the results, the same expression trend was obtained both in serum and tissues, and the expression of the four markers was the highest in malignant mammary tumours, with highly significant differences compared with the benign and healthy/paracancerous groups. By plotting the ROC curves, it was found that the results of combined tests were better than a single test and the combination of the four markers was the best for the early diagnosis. In conclusion, this can assist the clinical early diagnosis to a certain extent, and also provides some references and assistance for the development of tumor detection kits in clinical practice. Full article
(This article belongs to the Special Issue Companion Animals’ Molecular Oncology)
►▼ Show Figures

Figure 1

12 pages, 1521 KiB  
Article
Novel Y RNA-Derived Fragments Can Differentiate Canine Hepatocellular Carcinoma from Hepatocellular Adenoma
by Norio Ushio, Md Nazmul Hasan, Mohammad Arif and Naoki Miura
Animals 2023, 13(19), 3054; https://doi.org/10.3390/ani13193054 - 28 Sep 2023
Viewed by 774
Abstract
Hepatocellular carcinomas (HCC) are common tumors, whereas hepatocellular adenomas (HCA) are rare, benign tumors in dogs. The aberrant expression of noncoding RNAs (ncRNAs) plays a pivotal role in HCC tumorigenesis and progression. Among ncRNAs, micro RNAs have been widely researched in human HCC, [...] Read more.
Hepatocellular carcinomas (HCC) are common tumors, whereas hepatocellular adenomas (HCA) are rare, benign tumors in dogs. The aberrant expression of noncoding RNAs (ncRNAs) plays a pivotal role in HCC tumorigenesis and progression. Among ncRNAs, micro RNAs have been widely researched in human HCC, but much less widely in canine HCC. However, Y RNA-derived fragments have yet to be investigated in canine HCC and HCA. This study targeted canine HCC and HCA patients. We used qRT-PCR to determine Y RNA expression in clinical tissues, plasma, and plasma extracellular vesicles, and two HCC cell lines (95-1044 and AZACH). Y RNA was significantly decreased in tissue, plasma, and plasma extracellular vesicles for canine HCC versus canine HCA and healthy controls. Y RNA was decreased in 95-1044 and AZACH cells versus normal liver tissue and in AZACH versus 95-1044 cells. In plasma samples, Y RNA levels were decreased in HCC versus HCA and Healthy controls and increased in HCA versus Healthy controls. Receiver operating characteristic analysis showed that Y RNA could be a promising biomarker for distinguishing HCC from HCA and healthy controls. Overall, the dysregulated expression of Y RNA can distinguish canine HCC from HCA. However, further research is necessary to elucidate the underlying Y RNA-related molecular mechanisms in hepatocellular neoplastic diseases. To the best of our knowledge, this is the first report on the relative expression of Y RNA in canine HCC and HCA. Full article
(This article belongs to the Special Issue Companion Animals’ Molecular Oncology)
►▼ Show Figures

Figure 1

Review

Jump to: Research

20 pages, 2240 KiB  
Review
Epigenetic Alterations in Canine Malignant Lymphoma: Future and Clinical Outcomes
by Esperanza Montaner-Angoiti, Pablo Jesús Marín-García and Lola Llobat
Animals 2023, 13(3), 468; https://doi.org/10.3390/ani13030468 - 29 Jan 2023
Cited by 2 | Viewed by 2254
Abstract
Canine malignant lymphoma is a common neoplasia in dogs, and some studies have used dogs as a research model for molecular mechanisms of lymphomas in humans. In two species, chemotherapy is the treatment of choice, but the resistance to conventional anticancer drugs is [...] Read more.
Canine malignant lymphoma is a common neoplasia in dogs, and some studies have used dogs as a research model for molecular mechanisms of lymphomas in humans. In two species, chemotherapy is the treatment of choice, but the resistance to conventional anticancer drugs is frequent. The knowledge of molecular mechanisms of development and progression of neoplasia has expanded in recent years, and the underlying epigenetic mechanisms are increasingly well known. These studies open up new ways of discovering therapeutic biomarkers. Histone deacetylases and demethylase inhibitors could be a future treatment for canine lymphoma, and the use of microRNAs as diagnosis and prognosis biomarkers is getting closer. This review summarises the epigenetic mechanisms underlying canine lymphoma and their possible application as treatment and biomarkers, both prognostic and diagnostic. Full article
(This article belongs to the Special Issue Companion Animals’ Molecular Oncology)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop